DRMA Dermata Therapeutics
- 2.2800
- -0.3000-11.63%
- 2.3460
- +0.0660+2.89%
Dermata Therapeutics News
Express News | Dermata Therapeutics Entered Into ATM Agreement With H.C. Wainwright Providing For Sale By Co Of $1.2M Of Its Shares Of Common Stock From Time To Time
Express News | Dermata Therapeutics - Aggregate Market Value of Shares of Common Stock Eligible for Sale Under Atm Prospectus Supplement Is Currently $1.2 Mln
Express News | Dermata Therapeutics-Entered Into Atm Agreement With H.c. Wainwright Providing for Sale by Co of Its Shares of Common Stock From Time to Time
Express News | Dermata Therapeutics Inc - on June 4 Got Letter From Nasdaq That Company Has Regained Compliance With Minimum Bid Price Requirement
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersReshape Lifesciences (NASDAQ:RSLS) shares rose 88.9% to $0.39 during Tuesday's after-market session. The market value of their outstanding shares is at $9.2 million. Dermata Therapeutics (NASDA
Acne Vulgaris Market to Register Sustainable Growth by 2034, Examines DelveInsight | Key Companies - Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corporation
The dynamics of the acne vulgaris market are anticipated to change in the coming years owing to the increase in the prevalent cases of acne vulgaris, along with the expected launch of emerging therap
Dermata Therapeutics (DRMA) Receives a Buy From Maxim Group
Dermata Therapeutics Entred Agreements For The Immediate Exercise Of Certain Warrants To Purchase Up To An Aggregate Of 516,336 Shares Of The Co's Common Stock, Having Exercise Prices Of $9.7665 And $32.40 Per Share
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions,
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. , a late-stage biotechnology company focused on the treatment of medical
10-Q: Quarterly report
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Dermata Therapeutics Unveils Key Financial Results and Efficiencies
Express News | Dermata Therapeutics Q1 2024 GAAP EPS $(0.47) Misses $(0.36) Estimate
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track -- Dermata continues discussions with potential botulinum toxin partners for DMT410 -- Receive
Dermata Therapeutics To Carry Out 1-for-15 Reverse Stock Split On May 16th, 2024
May 15th - $Dermata Therapeutics(DRMA.US)$ is about to implement a 1-for-15 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from May 16th, 2024.$Dermata Therapeu
Dermata Therapeutics Enhances Equity Plan and Approves Stock Split
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersAdial Pharmaceuticals (NASDAQ:ADIL) stock rose 34.2% to $2.59 during Monday's pre-market session. The company's market cap stands at $10.5 million. NKGen Biotech (NASDAQ:NKGN) shares moved upwa
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersDynatronics (NASDAQ:DYNT) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap stands at $3.3 million. BioRestorative Therapies (NASDAQ:BRTX) shares rose 23.4
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
Maxim Group Sticks to Their Buy Rating for Dermata Therapeutics (DRMA)
Analysis
Price Target
No Data
